

DAFTAR PUSTAKA

- 1 Gonzalez ER. For puberty that comes too early, new treatment highly effective. *J Am Med Assoc* 1982; **248**: 1149–1151.
- 2 Unit Kerja Koordinasi Endokrinologi Ikatan Dokter Anak Indonesia. *Panduan Praktek Klinis Ikatan Dokter Anak Indonesia: Diagnosis dan Tata Laksana Pubertas Prekoks Sentral*. Badan Penerbit Ikatan Dokter Anak Indonesia, 2017.
- 3 Pulungan AB, Soesanti F. Pubertas Normal dan Gangguannya: Pubertas Prekoks. In: Batubara JR, AAP BT, Pulungan AB (ed). *Buku Ajar Endokrinologi Anak*. Badan Penerbit Ikatan Dokter Anak Indonesia, 2018, hal 102–111.
- 4 Ng SM, Kumar Y, Cody D, Smith CS, Didi M. Cranial MRI scans are indicated in all girls with central precocious puberty. *Arch Dis Child* 2003; **88**: 414–418.
- 5 Kim EY, Lee MI. Psychosocial aspects in girls with idiopathic precocious puberty. *Psychiatry Investig* 2012; **9**: 25–28.
- 6 Muir A. Precocious Puberty. *Pediatr Rev* 2006; **27**: 373–381.
- 7 Pulungan AB. Pubertas Normal dan Gangguannya: Pubertas Normal. In: Batubara JR, AAP BT, Pulungan AB (ed). *Buku Ajar Endokrinologi Anak*. Badan Penerbit Ikatan Dokter Anak Indonesia, 2018, hal 92–101.
- 8 Teles MG, Bianco SD, Brito VN, Trarbach EB, Kuohung W, Kaiser UB *et al*. A GPR54-activating mutation in a patient with central precocious puberty. *N Engl J Med* 2008; **358**: 709–715.
- 9 Marshall W, Tanner J. Variations in pattern of pubertal changes in girls. *Arch Dis Child* 1969; : 291–303.
- 10 Bridges NA, Christopher JA, Hindmarsh PC, Brook CGD. Sexual precocity: sex incidence and aetiology. *Arch Dis Child* 1994; **70**: 116–118.
- 11 Latronico AC, Brito VN, Carel J-C. Causes, diagnosis, and treatment of central precocious puberty. *Lancet Diabetes Endocrinol* 2016; **4**: 265–274.
- 12 Carel J-C, Leger J. Precocious puberty. *N Engl J Med* 2008; **358**: 2366–2377.
- 13 Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. *J Pediatr* 2011; **159**: 982–987.e1.

- 14 Durand A, Tauber M, Patel B, Dutailly P. Meta-analysis of paediatric patients with central precocious puberty treated with intramuscular triptorelin 11.25 mg 3-month prolonged-release formulation. *Horm Res Paediatr* 2017; **87**: 224–232.
- 15 Carel J-C, Lahlou N, Guazzarotti L, Joubert-Collin M, Roger M, Colle M *et al.* Treatment of central precocious puberty with depot leuprorelin. French Leuprorelin Trial Group. *Eur J Endocrinol* 1995; **132**: 699–704.
- 16 Jung MK, Song KC, Kwon AR, Chae HW, Kim DH, Kim H-S. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone. *Ann Pediatr Endocrinol Metab* 2014; **19**: 214–9.
- 17 Li P, Li Y, Yang CL. Gonadotropin releasing hormone agonist treatment to increase final stature in children with precocious puberty. *Med (United States)* 2014; **93**: 1–8.
- 18 Brown JJ, Warne GL. Growth in precocious puberty. *Indian J Pediatr* 2006; **73**: 81–88.
- 19 Palmert MR, Mansfield MJ, Crowley WF, Crigler JF, Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. *J Clin Endocrinol Metab* 1999; **84**: 4480–4488.
- 20 Heger S, Partsch C-J, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density, and reproductive function. *J Clin Endocrinol Metab* 1999; **84**: 4583–4590.
- 21 Tremblay L, Frigon J-Y. Precocious puberty in adolescent girls: a biomarker of later psychosocial adjustment problems. *Child Psychiatry Hum Dev* 2005; **36**: 73–94.
- 22 Xhrouet-Heinrichs D, Lagrou K, Heinrichs C, Craen M, Doooms L, Malvaux P *et al.* Longitudinal study of behavioral and affective patterns in girls with central precocious puberty during long-acting triptorelin therapy. *Acta Paediatr* 1997; **86**: 808–15.
- 23 Boepple PA, Mansfield MJ, Wierman ME, Rudlin CR, Bode HH, Crigler JF *et al.* Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. *Endocr Rev* 1986; **7**: 24–33.
- 24 Franceschi R, Gaudino R, Marcolongo A, Gallo MC, Rossi L, Antoniazzi F *et al.*

- Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty. *Fertil Steril* 2010; **93**: 1185–1191.
- 25 Chiavaroli V, Liberati M, D’Antonio F, Masuccio F, Capanna R, Verrotti A *et al*. GnRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome. *Eur J Endocrinol* 2010; **163**: 55–62.
 - 26 Rosenfield RL. Identifying children at risk for polycystic ovary syndrome. *J Clin Endocrinol Metab* 2007; **92**: 787–796.
 - 27 Soetjningsih. *Tumbuh Kembang Anak*. EGC: Jakarta, 1995.
 - 28 World Health Organization. WHO growth reference: height-for-age GIRLS 5-19 years. 2007; : 1–7.
 - 29 Neely EK, Lee PA, Bloch CA, Larsen L, Yang D, Mattia-goldberg C *et al*. Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery. *Int J Pediatr Endocrinol* 2010; **2010**: 1–9.
 - 30 Carel J-C, Roger M, Ispas S, Tondou F, Lahlou N, Blumberg J *et al*. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. *J Clin Endocrinol Metab* 1999; **84**: 1973–1978.
 - 31 Karamizadeh Z, Amirhakimi A, Amirhakimi G. Effect of pubertal suppression on linear growth and body mass index; a two-year follow-up in girls with genetic short stature and rapidly progressive puberty. *Iran J Pediatr* 2014; **24**: 293–299.
 - 32 Bar A, Linder B, Sobel EH, Saenger P, DiMartino-Nardi J. Bayley-Pinneau method of height prediction in girls with central precocious puberty: correlation with adult height. *J Pediatr* 1995; **126**: 955–958.
 - 33 Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the greulich-pyle hand standards. *J Pediatr* 1952; **40**: 423–441.
 - 34 Bhatia S, Neely EK, Wilson DM. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. *Pediatrics* 2002; **109**: 1–6.
 - 35 Lee PA, Luce M, Bacher P. Monitoring treatment of central precocious puberty using

- basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation. *J Pediatr Endocrinol Metab* 2016; **29**: 1249–1257.
- 36 Pasquino AM, Pucarelli I, Segni M, Matrunola M, Cerrone F. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone. *J Clin Endocrinol Metab* 1999; **84**: 449–452.
 - 37 World Health Organization. WHO growth reference: BMI-for-age GIRLS 5-19 years. 2007; : 2–8.
 - 38 Li W, Liu Q, Deng X, Chen Y, Liu S, Story M. Association between obesity and puberty timing: a systematic review and meta-analysis. *Int J Environ Res Public Health* 2017; **14**: 1–13.
 - 39 Divall SA, Radovick S. Endocrinology of female puberty. *Current Opin Endocrinol Diabetes Obes* 2009; **16**: 1–4.
 - 40 Demerath EW, Li J, Sun SS, Chumlea WC, Remsberg KE, Czerwinski SA *et al*. Fifty-year trends in serial body mass index during adolescence in girls: the Fels Longitudinal Study. *The Am J Clin Nutr* 2004; **80**: 441–446.
 - 41 Benedet J, Lopes A da S, Adami F, Hinnig PDF, Vasconcelos F de A de. Association of sexual maturation with excess body weight and height in children and adolescents. *BioMed Cent Pediatr* 2014; **14**: 1–7.
 - 42 Williams VSL, Soliman AM, Barrett AM, Klein KO. Review and evaluation of patient-centered psychosocial assessments for children with central precocious puberty or early puberty. *J Pediatr Endocrinol Metab* 2018; **31**: 485–495.
 - 43 Poomthavorn P, Suphasit R, Mahachoklertwattana P. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment. *Gynecol Endocrinol* 2011; **27**: 524–528.
 - 44 Manjila S, Vogel TW, Chen Y, Rodgers MS, Cohen AR. Hypothalamic hamartoma simulating a suprasellar arachnoid cyst: resolution of precocious puberty following microsurgical lesion resection. *J Neurosurg Pediatr* 2014; **14**: 101–107.
 - 45 Pescovitz OH, Comite F, Hench K, Barnes K, McNemar A, Foster C *et al*. The NIH



experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. *J Pediatr* 1986; **108**: 47–54.

- 46 Chalumeau M, Chemaitilly W, Trivin C, Adan L, Bréart G, Brauner R. Central precocious puberty in girls: an evidence-based diagnosis tree to predict central nervous system abnormalities. *Pediatrics* 2002; **109**: 61–7.
- 47 Gilsanz V, Ratib O. *Hand bone age: a digital atlas of skeletal maturity*. Springer-Verlag: Berlin Heidelberg, 2005.